R&D Trends

Basilea awarded $100M BARDA contract for ceftobiprole program

Thursday, April 21, 2016

Basilea Pharmaceutica has announced that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services` Office of the Assistant Secretary for Preparedness and Response, has entered into a contract with Basilea Pharmaceutica International for the clinical phase III development aiming at regulatory approval of Basilea`s broad-spectrum antibiotic ceftobiprole in the U.S.

[Read More]

DNAnexus, Solvebio partner to make genomic data more actionable

Thursday, April 21, 2016

DNAnexus, a cloud-based genome informatics and data management provider, has announced a partnership with SolveBio, a global provider of Genomics Intelligence, to integrate the two platforms and provide seamless access to SolveBio’s curated data and analysis services. Researchers globally will have the ability to move quickly from genomic data analysis to interpretation, freeing up time to focus on generating uniquely actionable biological insights.

[Read More]

Cancer Centers, biopharmaceuticals collaborate on precision medicines

Wednesday, April 20, 2016

M2Gen, a healthcare informatics solutions company, has announced a collaboration with pharmaceutical companies and the Oncology Research Information Exchange Network (ORIEN), an alliance of cancer centers throughout the U.S. M2Gen also announced that Celgene will be the industry’s founding member of a network of participants joining in this new initiative. The launch of the ORIEN Avatar Research Program brings together the pre-eminent players in healthcare R&D pharmaceutical companies and academic cancer centers to find new treatments for millions of Americans battling advanced-stage cancers.

[Read More]

Analysis: U.S. Ranks 1st in national impact on global biopharma innovation policies

Wednesday, April 13, 2016

The U.S. ranks 1st in how its domestic policies support worldwide life sciences innovation, according to an analysis released by the Information Technology and Innovation Foundation (ITIF), a global technology policy think tank. Released on World Health Day, the findings come in a new report assessing 56 countries—which together comprise close to 90% of the world’s economy—on the extent to which their scientific research, drug pricing, and intellectual property policies contribute to global biopharmaceutical innovation.

[Read More]

Abpro, Essex Bio partner on antibody therapeutics

Tuesday, April 12, 2016

Abpro, an integrated life science company at the forefront of synthetic biology, has partnered with Essex Bio, a China-based biopharmaceutical company. Abpro and Essex will co-develop multiple monoclonal antibodies in immuno-oncology and ophthalmology by leveraging Abpro’s DiversImmune platform. Abpro received a $3.5M equity investment from Essex Bio and an undisclosed amount from affiliates, as part of the agreement.

[Read More]

Sosei subsidiary Heptares and Allergan partner

Thursday, April 7, 2016

Sosei Group‘s wholly-owned subsidiary Heptares Therapeutics has entered into a definitive agreement with Allergan Pharmaceuticals International, a wholly owned subsidiary of Allergan, a global pharmaceutical company, under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

[Read More]

FEI partners to form Cryo-EM research consortium

Tuesday, April 5, 2016

FEI has partnered to form the “Cambridge Pharmaceutical Cryo-EM Consortium.” Partners include five pharmaceutical companies—Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Center. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.

[Read More]